Statistical controversies in cancer research: Using standardized effect size graphs to enhance interpretability of cancer-related clinical trials with patient-reported outcomes

Melanie L Bell, M. H. Fiero, H. M. Dhillon, V. J. Bray, J. L. Vardy

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Patient reported outcomes (PROs) are becoming increasingly important in cancer studies, particularly with the emphasis on patient centered outcome research. However, multiple PROs, using different scales, with different directions of favorability are often used within a trial, making interpretation difficult. To enhance interpretability, we propose the use of a standardized effect size graph, which shows all PROs from a study on the same figure, on the same scale. Plotting standardized effects with their 95% confidence intervals (CIs) on a single graph clearly showing the null value conveys a comprehensive picture of trial results. We demonstrate how to create such a graph using data from a randomized controlled trial that measured 12 PROs at two time points. The 24 effect sizes and CIs are shown on one graph and clearly indicate that the intervention is effective and sustained.

Original languageEnglish (US)
Article numbermdx064
Pages (from-to)1730-1733
Number of pages4
JournalAnnals of Oncology
Volume28
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Clinical Trials
Research
Neoplasms
Patient Outcome Assessment
Confidence Intervals
Randomized Controlled Trials
Outcome Assessment (Health Care)
Patient Reported Outcome Measures
Direction compound

Keywords

  • Cancer
  • Effect size
  • Graphs
  • Patient-reported outcomes
  • Quality of life

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Statistical controversies in cancer research : Using standardized effect size graphs to enhance interpretability of cancer-related clinical trials with patient-reported outcomes. / Bell, Melanie L; Fiero, M. H.; Dhillon, H. M.; Bray, V. J.; Vardy, J. L.

In: Annals of Oncology, Vol. 28, No. 8, mdx064, 01.08.2017, p. 1730-1733.

Research output: Contribution to journalArticle

@article{c7e4b93021fe45738801bba7d4e75857,
title = "Statistical controversies in cancer research: Using standardized effect size graphs to enhance interpretability of cancer-related clinical trials with patient-reported outcomes",
abstract = "Patient reported outcomes (PROs) are becoming increasingly important in cancer studies, particularly with the emphasis on patient centered outcome research. However, multiple PROs, using different scales, with different directions of favorability are often used within a trial, making interpretation difficult. To enhance interpretability, we propose the use of a standardized effect size graph, which shows all PROs from a study on the same figure, on the same scale. Plotting standardized effects with their 95{\%} confidence intervals (CIs) on a single graph clearly showing the null value conveys a comprehensive picture of trial results. We demonstrate how to create such a graph using data from a randomized controlled trial that measured 12 PROs at two time points. The 24 effect sizes and CIs are shown on one graph and clearly indicate that the intervention is effective and sustained.",
keywords = "Cancer, Effect size, Graphs, Patient-reported outcomes, Quality of life",
author = "Bell, {Melanie L} and Fiero, {M. H.} and Dhillon, {H. M.} and Bray, {V. J.} and Vardy, {J. L.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1093/annonc/mdx064",
language = "English (US)",
volume = "28",
pages = "1730--1733",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Statistical controversies in cancer research

T2 - Using standardized effect size graphs to enhance interpretability of cancer-related clinical trials with patient-reported outcomes

AU - Bell, Melanie L

AU - Fiero, M. H.

AU - Dhillon, H. M.

AU - Bray, V. J.

AU - Vardy, J. L.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Patient reported outcomes (PROs) are becoming increasingly important in cancer studies, particularly with the emphasis on patient centered outcome research. However, multiple PROs, using different scales, with different directions of favorability are often used within a trial, making interpretation difficult. To enhance interpretability, we propose the use of a standardized effect size graph, which shows all PROs from a study on the same figure, on the same scale. Plotting standardized effects with their 95% confidence intervals (CIs) on a single graph clearly showing the null value conveys a comprehensive picture of trial results. We demonstrate how to create such a graph using data from a randomized controlled trial that measured 12 PROs at two time points. The 24 effect sizes and CIs are shown on one graph and clearly indicate that the intervention is effective and sustained.

AB - Patient reported outcomes (PROs) are becoming increasingly important in cancer studies, particularly with the emphasis on patient centered outcome research. However, multiple PROs, using different scales, with different directions of favorability are often used within a trial, making interpretation difficult. To enhance interpretability, we propose the use of a standardized effect size graph, which shows all PROs from a study on the same figure, on the same scale. Plotting standardized effects with their 95% confidence intervals (CIs) on a single graph clearly showing the null value conveys a comprehensive picture of trial results. We demonstrate how to create such a graph using data from a randomized controlled trial that measured 12 PROs at two time points. The 24 effect sizes and CIs are shown on one graph and clearly indicate that the intervention is effective and sustained.

KW - Cancer

KW - Effect size

KW - Graphs

KW - Patient-reported outcomes

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=85029286441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029286441&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx064

DO - 10.1093/annonc/mdx064

M3 - Article

C2 - 28327975

AN - SCOPUS:85029286441

VL - 28

SP - 1730

EP - 1733

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 8

M1 - mdx064

ER -